FDA Grants AltruBio AbGn-168H (Neihulizumab) Fast Track Designation in SR-aGVHD
2020
Sep
Initiate multiple dose phase study (Phase 1b) of AbGn-168H in patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD) in the United State.
Jun
Phase 2a anti-TNF α and/or anti-integrin refractory/intolerant Ulcerative Colitis trial completed with proof of Clinical efficacy achieved in the United States.
Jun
The Company changes its name to AltruBio Inc.
Apr
Complete single dose escalation, safety and initial efficacy in Phase 1a clinical trial study of AbGn-168H in patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD) in the United State.
Jan
Dr. Judy Chou, Joins the company as president & CEO.
2018
Mar
FDA Grants AbGn-168H (Neihulizumab) Orphan Drug Designation in treating aGVHD.
2016
Jan
Proof of initial efficacy was demonstrated in a Phase-2a clinical trial study of AbGn-168H in patients with psoriatic arthritis.
2015
Feb
AbGn-168H’s phase-II clinical trial targeting psoriasis completed in the United States.
2014
Feb
Phase 2a clinical trial of AbGn-168H in patients with psoriasis completed in the U.S.
2011
Nov
Phase 1 clinical trial of AbGn-168H completed in healthy volunteers.
2006
Jun
AbGenomics International Inc. (AbGUS) formed in the United States.
2005
May
Patent application for AbGn-168 were filed with USPTO and WIPO, a monoclonal antibody for the frestment of multiple immunological diseases.
